 |
|
Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy
A Randomized Controlled Trial
Richard T. Davey Jr, MD;
Robert L. Murphy, MD;
Frank M. Graziano, MD, PhD;
Stephen L. Boswell, MD;
Andrew T. Pavia, MD;
Margarita Cancio, MD;
Jeffrey P. Nadler, MD;
Doreen G. Chaitt, RN, MPH;
Robin L. Dewar, PhD;
David K. Sahner, MD;
Anne-Marie Duliege, MD, MS;
William B. Capra, PhD;
Wai-Ping Leong, MS;
Martin A. Giedlin, PhD;
H. Clifford Lane, MD;
James O. Kahn, MD
JAMA. 2000;284:183-189.
Context While interleukin 2 (IL-2) is capable of inducing a marked expansion of the CD4 T-lymphocyte pool, limited data exist on whether IL-2 treatment can add significantly to the immunologic and virologic effects of potent antiretroviral therapy (ART).
Objective To determine the rate and magnitude of CD4 cell recovery and viral suppression when using a combination therapy of IL-2 and ART compared with ART alone.
Design and Setting Randomized, controlled multicenter trial conducted from April 1996 through April 1998 at 8 clinical sites in the United States.
Patients Eighty-two adult outpatients who were infected with human immunodeficiency virus (HIV) and had baseline CD4 cell counts of 200 x 106/L to 500 x 106/L and baseline RNA levels of fewer than 10,000 copies/mL were randomized; 78 completed the study.
Interventions Thirty-nine patients were randomly assigned to receive a combination therapy of subcutaneous IL-2 (administered in 5-day courses every 8 weeks at a starting dosage of 7.5 mIU twice per day) and ART; 43 were to receive ART therapy alone.
Main Outcome Measures Interleukin 2 safety and differential effects on CD4 cell counts, CD4 cell percentages, and plasma HIV RNA levels.
Results The mean (SD) percentage increase in CD4 cell counts at 1 year for patients who received IL-2 was 112% (113%) compared with 18% (35%) in recipients of ART alone (P<.001). Both groups had mean (SD) increases in CD4 cell percentage: from 20.4% (6.3%) to 32.3% (12.4%) for the combination therapy group compared with 20.4% (5.1%) to 23.0% (7.2%) for recipients of ART alone (P<.001). Using a sensitive viral RNA assay, mean viral load changes were -0.28 and 0.09 log10 copies for IL-2 recipients and control patients, respectively (P=.03). Twenty (67%) of 30 evaluable patients receiving IL-2 achieved final viral loads of fewer than 50 copies/mL compared with 13 (36%) of 36 control patients (P=.02). Toxic effects were common among patients who received IL-2 and were managed with antipyretics, hydration, rest, and dosage reduction as needed.
Conclusions Intermittent therapy with IL-2 and ART produced a substantially greater increase in CD4 cells and was associated with a larger decrease in viral load than ART alone. Clinical end-point trials will be necessary to determine whether the enhanced viral suppression and CD4 cell increases associated with IL-2 therapy will translate into improved clinical outcomes.
Author Affiliations: National Institute of Allergy and Infectious Diseases (Drs Davey and Lane) and Department of Critical Care Medicine (Ms Chaitt), National Institutes of Health, Bethesda, Md; Division of Infectious Diseases, Northwestern University, Chicago, Ill (Dr Murphy); Department of Medicine, University of Wisconsin, Madison (Dr Graziano); Fenway Community Health Center, Boston, Mass (Dr Boswell); Division of Pediatric Infectious Diseases, University of Utah, Salt Lake City (Dr Pavia); St Joseph's Hospital (Dr Cancio) and Division of Infectious Diseases, University of South Florida (Dr Nadler), Tampa; Science Applications International Corp, Frederick, Md (Dr Dewar); Chiron Corp, Emeryville, Calif (Drs Sahner, Duliege, Capra, and Giedlin and Ms Leong); and San Francisco General Hospital and the University of California at San Francisco Center for AIDS Research (Dr Kahn).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Viral Load in Treatment With Antiretroviral Therapy and Interleukin 2
Jean-Pierre Aboulker, Richard T. Davey, Jr, and William B. Capra
JAMA. 2000;284(16):2055-2056.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Immune Restoration With Antiretroviral Therapies: Implications for Clinical Management
Michael M. Lederman and Hernan Valdez
JAMA. 2000;284(2):223-228.
ABSTRACT
| FULL TEXT
Interleukin 2 Treatment for HIV Infection
Joel Blankson and Robert F. Siliciano
JAMA. 2000;284(2):236-238.
EXTRACT
| FULL TEXT
July 12, 2000
JAMA. 2000;284(2):249-250.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Sereti et al.
Blood 2009;113:6304-6314.
ABSTRACT
| FULL TEXT
Comparisons of CD8+ T Cells Specific for Human Immunodeficiency Virus, Hepatitis C Virus, and Cytomegalovirus Reveal Differences in Frequency, Immunodominance, Phenotype, and Interleukin-2 Responsiveness
Jagannathan et al.
J. Virol. 2009;83:2728-2742.
ABSTRACT
| FULL TEXT
Naive T-Cell Dynamics in Human Immunodeficiency Virus Type 1 Infection: Effects of Highly Active Antiretroviral Therapy Provide Insights into the Mechanisms of Naive T-Cell Depletion
Di Mascio et al.
J. Virol. 2006;80:2665-2674.
ABSTRACT
| FULL TEXT
Uncoupled Anti-HIV and Immune-Enhancing Effects when Combining IFN-{alpha} and IL-7
Audige et al.
J. Immunol. 2005;175:3724-3736.
ABSTRACT
| FULL TEXT
IL-2 Responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2R{beta} transgenic mice
Gesbert et al.
Int Immunol 2005;17:1093-1102.
ABSTRACT
| FULL TEXT
Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
Marchetti et al.
J Antimicrob Chemother 2005;55:401-409.
ABSTRACT
| FULL TEXT
Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251
Nacsa et al.
J. Immunol. 2005;174:1913-1921.
ABSTRACT
| FULL TEXT
IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation
Sereti et al.
Blood 2004;104:775-780.
ABSTRACT
| FULL TEXT
Effect of Pregnancy and Human Immunodeficiency Virus Infection on Intracellular Interleukin-2 Production Patterns
Sutton et al.
CVI 2004;11:780-785.
ABSTRACT
| FULL TEXT
Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection
Farel et al.
Blood 2004;103:3282-3286.
ABSTRACT
| FULL TEXT
An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory
Saavedra-Lozano et al.
Proc. Natl. Acad. Sci. USA 2004;101:2494-2499.
ABSTRACT
| FULL TEXT
Antigen-Presenting Cell Modulation Induces a Memory Response to p24 in Peripheral Blood Leukocytes from Human Immunodeficiency Virus-Infected Individuals
Kolber and Saenz
CVI 2003;10:757-763.
ABSTRACT
| FULL TEXT
Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy
Tryniszewska et al.
J. Immunol. 2002;169:5347-5357.
ABSTRACT
| FULL TEXT
Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells
Sereti et al.
Blood 2002;100:2159-2167.
ABSTRACT
| FULL TEXT
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2002;288:222-235.
ABSTRACT
| FULL TEXT
Exogenous Interleukin-2 Administration Corrects the Cell Cycle Perturbation of Lymphocytes from Human Immunodeficiency Virus-Infected Individuals
Paiardini et al.
J. Virol. 2001;75:10843-10855.
ABSTRACT
| FULL TEXT
Immunological Effects of Interleukin-2 Therapy in Human Immunodeficiency Virus-Positive Subjects
De Paoli
CVI 2001;8:671-677.
FULL TEXT
Phase 1B Study of Subcutaneously Administered Interleukin 2 in Combination with 13-cis Retinoic Acid as Maintenance Therapy in Advanced Cancer
Recchia et al.
Clin. Cancer Res. 2001;7:1251-1257.
ABSTRACT
| FULL TEXT
Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 x 106/L CD4 Cell Counts: A Randomized Controlled Trial
Kahn et al.
JAMA 2000;284:2193-2202.
ABSTRACT
| FULL TEXT
Viral Load in Treatment With Antiretroviral Therapy and Interleukin 2
Aboulker et al.
JAMA 2000;284:2055-2056.
FULL TEXT
Intermittent IL-2 Plus Potent Antiretroviral Therapy
JWatch Infect. Diseases 2000;2000:7-7.
FULL TEXT
Intermittent IL-2 Plus Potent Antiretroviral Therapy
JWatch Infect. Diseases 2000;2000:4-4.
FULL TEXT
The Role of Interleukin-2 in HIV Treatment
JWatch General 2000;2000:2-2.
FULL TEXT
Interleukin 2 Treatment for HIV Infection
Blankson and Siliciano
JAMA 2000;284:236-238.
FULL TEXT
|
